1. Home
  2. >Research
  3. >Scalable System Wide Cyp2c19 Pharmacogenomic Testing Reveals 38 Excess Incidence Of Adverse Events In Metabolizers Receiving Inappropriate Prescriptions
Skip to main content
Research

Scalable system-wide CYP2C19 pharmacogenomic testing reveals 38% excess incidence of adverse events in metabolizers receiving inappropriate prescriptions

Natalie TelisMarch 19, 2025Published Research

Ready to see the whole picture?

Connect with our team to discover how Helix can transform your approach to genomic medicine.